{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:06:16Z","timestamp":1790057176914,"version":"4.0.1"},"reference-count":23,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2026.13275","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:04:52Z","timestamp":1787220292000},"page":"1-6","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective study of infusion\u2011related reactions in subcutaneous daratumumab administration in Japan"],"prefix":"10.3892","volume":"32","author":[{"given":"Yoko","family":"Ino","sequence":"first","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhide","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuka","family":"Ito","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yamagishi","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futa","family":"Takemura","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senji","family":"Kasahara","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmaceutical Health Care and Promotion, Gifu Pharmaceutical University, Gifu 501\u20111196, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"key20260922084605_b1-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"key20260922084605_b2-ETM-32-4-13275"},{"key":"key20260922084605_b3-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"key":"key20260922084605_b4-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/bjh.16980","article-title":"Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): An open-label phase II study","volume":"192","author":"Chari","year":"2021","journal-title":"Br J Haematol"},{"key":"key20260922084605_b5-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","article-title":"Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): An open-label, randomised, phase 3 trial","volume":"22","author":"Dimopoulos","year":"2021","journal-title":"Lancet Oncol"},{"issue":"102922","key":"key20260922084605_b6-ETM-32-4-13275","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102922","article-title":"Management of infusion-related reactions in cancer therapy: Strategies and challenges","volume":"9","author":"Barroso","year":"2024","journal-title":"ESMO Open"},{"key":"key20260922084605_b7-ETM-32-4-13275"},{"key":"key20260922084605_b8-ETM-32-4-13275","first-page":"1","article-title":"Safety of SC daratumumab in the treatment of Plasma-cell disorders: A Single-center experience","volume":"13","author":"Jung","year":"2023","journal-title":"J Hematol Oncol Pharm"},{"key":"key20260922084605_b9-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1002\/cncr.31706","article-title":"Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma","volume":"124","author":"Chari","year":"2018","journal-title":"Cancer"},{"key":"key20260922084605_b10-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"e777","DOI":"10.1016\/j.clml.2020.05.024","article-title":"Evaluation of montelukast for the prevention of infusion-related reactions with daratumumab","volume":"20","author":"Moore","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20260922084605_b11-ETM-32-4-13275","doi-asserted-by":"crossref","first-page":"706","DOI":"10.5649\/jjphcs.45.706","article-title":"Retrospective Study on the safety of daratumumab in Japanese relapsed or refractory multiple myeloma and search for risk factors for infusion related reaction","volume":"45","author":"Nakagawa","year":"2019","journal-title":"Iryo Yakugaku (Jpn J Pharm Health Care Sci)"},{"key":"key20260922084605_b12-ETM-32-4-13275","first-page":"61","article-title":"Retrospective study on infusion related reactions during the first administration of daratumumab intravenous infusion in patients with multiple myeloma","volume":"58","author":"Iwamoto","year":"2022","journal-title":"J Jpn Soc Hosp Pharm"},{"key":"key20260922084605_b13-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s11523-023-01001-4","article-title":"Safety of subcutaneous daratumumab in anti-CD38 monoclonal antibody-na\u00efve patients with plasma cell disorders: A multicenter real-life experience","volume":"18","author":"De Novellis","year":"2023","journal-title":"Target Oncol"},{"key":"key20260922084605_b14-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00277-021-04405-2","article-title":"Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: Subgroup analyses of the Noninferiority, phase 3 COLUMBA study","volume":"100","author":"Iida","year":"2021","journal-title":"Ann Hematol"},{"key":"key20260922084605_b15-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-019-02676-0","article-title":"JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-overview","volume":"110","author":"Omachi","year":"2019","journal-title":"Int J Hematol"},{"key":"key20260922084605_b16-ETM-32-4-13275"},{"key":"key20260922084605_b17-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/oncolo\/oyae158","article-title":"Evaluation of administration-related reactions with subcutaneous daratumumab with and without premedication","volume":"29","author":"Padmaraju","year":"2024","journal-title":"Oncologist"},{"key":"key20260922084605_b18-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1080\/10428194.2017.1306648","article-title":"Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: Results from a retrospective, multicenter study of 374 patients","volume":"58","author":"D'Arena","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"e000346","key":"key20260922084605_b19-ETM-32-4-13275","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000346","article-title":"High incidence of cetuximab-related infusion reactions in head and neck patients","volume":"3","author":"Palomar Coloma","year":"2018","journal-title":"ESMO Open"},{"key":"key20260922084605_b20-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"437","DOI":"10.6004\/jadpro.2024.15.7.2","article-title":"Obinutuzumab infusion-related reactions: Multicenter retrospective evaluation of incidence, severity, and risk factors","volume":"15","author":"Zacholski","year":"2024","journal-title":"J Adv Pract Oncol"},{"key":"key20260922084605_b21-ETM-32-4-13275","doi-asserted-by":"crossref","first-page":"631","DOI":"10.5649\/jjphcs.47.631","article-title":"Search for risk factors influencing the occurrence of infusion reaction after initial treatment with obinutuzumab","volume":"47","author":"Kuromatsu","year":"2021","journal-title":"Iryo Yakugaku (Jpn J Pharm Health Care Sci)"},{"key":"key20260922084605_b22-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1182\/blood.2020009754","article-title":"Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development","volume":"138","author":"Daniel","year":"2021","journal-title":"Blood"},{"key":"key20260922084605_b23-ETM-32-4-13275","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: A real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:46:14Z","timestamp":1790055974000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2026.13275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,20]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2026.13275","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}